Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 9/20 | 0.69 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | FPR1 | P21462 | 2/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4969124 | 0.89 | CAPN1 (0.67) | CAPN1CTSKCA1CA2CTSL | |
| SCHEMBL4970169 | 0.88 | CAPN1 (0.67) | CAPN1CTSKCA1CA2CTSL | |
| SCHEMBL4969603 | 0.88 | CAPN1 (0.66) | CAPN1CTSKCTSLCTSS | |
| SCHEMBL4973417 | 0.86 | CAPN1 (0.68) | CAPN1CTSKCA1CA2CTSL | |
| SCHEMBL4970138 | 0.81 | CAPN1 (0.69) | CAPN1CTSK | |
| SCHEMBL4970175 | 0.81 | CAPN1 (1.00) | CAPN1 | |
| SCHEMBL4972733 | 0.79 | CAPN1 (0.68) | CAPN1CTSKCTSLCTSS | |
| SCHEMBL7513284 | 0.77 | CAPN1 (0.53) | CAPN1CTSKCTSLCTSS | |
| SCHEMBL4966952 | 0.76 | CAPN1 (0.67) | CAPN1CTSKCTSLCTSS | |
| SCHEMBL4968800 | 0.72 | CAPN1 (0.64) | CAPN1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1489076-B1 | CYCLIC HEMIACETAL DERIVATIVE AND USE THEREOF | SENJU PHARMA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-7202274-B2 | Cyclic hemiacetal derivative and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-10 | — | — | US | disclosed |
| US-20050119499-A1 | Cyclic hemiacetal derivative and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-1489076-A1 | CYCLIC HEMIACETAL DERIVATIVE AND USE THEREOF | Senju Pharmaceutical Co., Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119499-A1 | Cyclic hemiacetal derivative and use thereof | CAPN1, CAPN2, CAPNS1 | CAPN1 1/4885CTSK 798/4885CA1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.